{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:12:03Z","timestamp":1788448323330,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Non-small-cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (<jats:italic toggle=\"yes\">HER2<\/jats:italic>) exon 20 mutant occurs in 3% of NSCLCs. Targeted agents for this population remain an unmet need. In this analysis, we pooled-analyzed the efficacy and safety of poziotinib, a novel tyrosine kinase inhibitor, in <jats:italic toggle=\"yes\">HER2<\/jats:italic> exon 20 mutant NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were systematically searched on March 9, 2022. The primary endpoints were objective response rate (ORR) and disease control rate. The secondary endpoint was treatment-related adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Three prospective clinical trials, involving 126 patients, were identified. The pooled ORR and disease control rate of poziotinib in <jats:italic toggle=\"yes\">HER2<\/jats:italic> exon 20 mutant NSCLC were 27% (95% CI, 19\u201335) and 72% (95% CI, 64\u201380), respectively. Patients with G778_P780dupGSP had the highest ORR (88%; 95% CI, 33\u2013100; n\u2005=\u200512), followed by Y772_A775dupYVMA (20%; 95% CI, 12\u201330; n\u2005=\u200588) and G776delinsVC (19%; 95% CI, 0\u201350; n\u2005=\u200513). The most common grade 3 to 4 treatment-related adverse events were skin rash (36%), diarrhea (23%), and oral mucositis (13%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Poziotinib demonstrates moderate antitumor activity in previously treated <jats:italic toggle=\"yes\">HER2<\/jats:italic> exon 20 mutant NSCLC patients with a manageable safety profile. In addition, different subgroup mutations show various benefits of poziotinib treatment. Large-scale and multiarm clinical trials are warranted to confirm a suitable population and therapeutic strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031337","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T19:12:21Z","timestamp":1667848341000},"page":"e31337","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-7721","authenticated-orcid":false,"given":"Bi-Cheng","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Hua","family":"Kuang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Xiu","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-He","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazieres","year":"2016","journal-title":"Ann Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.21.01113","article-title":"Poziotinib for patients with HER2 Exon 20 mutant non-small-cell lung cancer: results from a phase II trial","volume":"40","author":"Elamin","year":"2022","journal-title":"J Clin Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 Exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.21.01455","article-title":"Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial","volume":"40","author":"Mazieres","year":"2022","journal-title":"J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1016\/j.cllc.2018.05.018","article-title":"Clinical activity of Pan-HER inhibitors against HER2-mutant lung adenocarcinoma","volume":"19","author":"Oh","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2021.08.2125","article-title":"LBA46 efficacy and safety of poziotinib in treatment-na\u00efve NSCLC harboring HER2 exon 20 mutations: a multinational phase II study (ZENITH20-4)","volume":"32","author":"Cornelissen","year":"2021","journal-title":"Ann Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejca.2021.02.038","article-title":"Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program","volume":"149","author":"Prelaj","year":"2021","journal-title":"Eur J Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","article-title":"Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: The PEONY phase 3 randomized clinical trial","volume":"6","author":"Shao","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:19:21Z","timestamp":1746328761000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":15,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031337","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]}}}